Wealthspire Advisors (Maryland)’s Supernus Pharmaceuticals SUPN Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-326	Closed	-$11K	–	1825
2019 Q1	$11K	Buy	326 +45	+16%	+$1.67K	﹤0.01%	1502
2018 Q4	$9K	Sell	281 -32	-10%	-$1.38K	﹤0.01%	1516
2018 Q3	$16K	Sell	313 -22	-7%	-$1.09K	﹤0.01%	1392
2018 Q2	$20K	Buy	335 +22	+7%	+$1.14K	﹤0.01%	1318
2018 Q1	$14K	Buy	313 +37	+13%	+$1.54K	﹤0.01%	1436
2017 Q4	$11K	Buy	276 +83	+43%	+$3.28K	﹤0.01%	1560
2017 Q3	$8K	Buy	193 +8	+4%	+$346	﹤0.01%	1659
2017 Q2	$8K	Buy	+185	New	+$6.58K	﹤0.01%	1628

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s SUPN Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 326 shares — an estimated $11K sold.

Wealthspire Advisors (Maryland) first reported a position in SUPN in Q2 2017 and held it in 8 quarters. The position peaked at $20K in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 326 Supernus Pharmaceuticals shares in Q2 2019, an estimated $11K.
Wealthspire Advisors (Maryland) first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Wealthspire Advisors (Maryland)'s Supernus Pharmaceuticals position peaked at $20K in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.